ホーム › 急性骨髄性白血病 › ペンシルベニア › Philadelphia
Philadelphia、PAにおける急性骨髄性白血病の臨床試験
Philadelphiaとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する34件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Thomas Jefferson University Hospital, Philadelphia
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
被験者募集中第1相
- Children's Hospital of Philadelphia, Philadelphia
Assessment of Geriatric Evaluations Impact on New AML Guidance
被験者募集中観察研究
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · 22マイル先
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
被験者募集中観察研究
- Children's Hospital of Philadelphia, Philadelphia
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Thomas Jefferson University Hospital, Philadelphia
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25マイル先
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
被験者募集中第1/2相
- University of Pennsylvania, Philadelphia
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
被験者募集中第1相
- UPENN Perelman Center for Advanced Medicine, Philadelphia
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
被験者募集中第3相
- Children's Hospital of Philadelphia, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25マイル先
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25マイル先
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Children's Hospital of Philadelphia, Philadelphia
- Nemours Alfred I. Dupont Hospital for Children, Wilmington · 25マイル先
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
被験者募集中第3相
- University of Pennsylvania, Philadelphia
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
被験者募集中第2/3相
- University of Pennsylvania, Philadelphia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
被験者募集中第1相
- Children's Hospital of Philadelphia, Philadelphia
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
被験者募集中第2相
- Penn Medicine Abramson Cancer Center, Philadelphia
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
被験者募集中第1相
- University of Pennsylvania, Philadelphia
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
被験者募集中
- Children's Hospital of Philadelphia, Philadelphia
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- Children's Hospital of Philadelphia, Philadelphia
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Children's Hospital of Philadelphia, Philadelphia
- Nemours - Alfred I. duPont Hospital for Children, Brandywine · 21マイル先
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
被験者募集中第1/2相
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
被験者募集中第1相
- University of Pennsylvania, Philadelphia
Massage Impact on Sleep in Pediatric Oncology
被験者募集中
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Phase IB/II of CPX-351 for Relapse Prevention in AML
被験者募集中第1/2相
- University of Pennsylvania, Philadelphia
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
被験者募集中第1相
- Thomas Jefferson University Hospital, Philadelphia
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- Hospital of the University of Pennsylvania, Philadelphia
Tazemetostat and Palbociclib With CPX-351for R/R AML
被験者募集中第1相
- Thomas Jefferson University Hospital, Philadelphia
Home Blood Transfusions
被験者募集中
- Thomas Jefferson University Hospital, Philadelphia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
被験者募集中健康なボランティア歓迎
- University of Pennsylvania, Philadelphia
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
- Washington, DC24件の研究
Philadelphiaにおける他の研究
- がん（全種類）59件の研究
- 乳がん56件の研究
- 非小細胞肺癌51件の研究
- 転移性癌46件の研究
- 前立腺がん44件の研究
- 大腸癌44件の研究
- 卵巣がん44件の研究
- 肺がん36件の研究
- 心不全31件の研究
- 子宮内膜がん28件の研究
- うつ病26件の研究
- 膵臓がん26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。